Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo

Journal of Immunology

Volumn 164, Issue 3, 2000, Pages 1617-1624

  Hartmann, Gunther ^a,b   Weeratna, Risini D ^c   Ballas, Zuhair K ^a,d   Payette, Paul ^c   Blackwell, Sue ^a   Suparto, Irma ^e   Rasmussen, Wendy L ^d   Waldschmidt, Marianella ^h   Sajuthi, Dondin ^e   Purcell, Robert H ^f   Davis, Heather L ^c,g   Krieg, Arthur M ^a,d,g  

^a UNIVERSITY OF IOWA   (United States)

^b CpG ImmunoPharmaceuticals GmbH   (Germany)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e BOGOR AGRICULTURAL UNIVERSITY   (Indonesia)

^f NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^g PFIZER INC   (United States)

^h 540 EMRB ^*

Author keywords

[No Author keywords available]

Indexed keywords

OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE;

ANIMAL CELL; ARTICLE; CHIMPANZEE; DNA SEQUENCE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY;

EID: 0034142182     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.3.1617     Document Type: Article

References (44)

1. Messina, J. P., G. S. Gilkeson, and D. S. Pisetsky, 1991. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J. Immunol. 147:1759.
2. Tokunaga, T., H. Yamamoto, S. Shimada, H. Abe, T. Fukuda, Y. Fujisawa, Y. Furutani, O. Yano, T. Kataoka, T. Sudo, et al. 1984. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Natl. Cancer Inst. 72:955.
3. Bird, A. P. 1986. CpG-rich isiands and the function of DNA methylation. Nature 321:209.
4. Cardon, L. R., C. Burge, D. A. Clayton, and S. Karlin. 1994. Pervasive CpG suppression in animal mitochondrial genomes. Proc. Natl. Acad. Sci. USA 91:3799.
5. Krieg, A. M., A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzky, and D. M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546.
6. Yi, A. K., M. Chang, D. W. Peckham, A. M. Krieg, and R. F. Ashman. 1998. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J. Immunol. 160:5898.
7. Krieg, A. M., A. K. Yi, J. Schorr, and H. L. Davis. 1998. The role of CpG dinucleotides in DNA vaccines. Trends Microbiol. 6:23.
8. Halpern, M.D., R.J. Kurlander, and D.S. Pisetsky. 1996. Bacterial DNA induces murine interferon-γ production by stimulation of interleukin-12 and tumor necrosis factor-α. Cell Immunol. 167:72.
9. Ballas, Z. K., W. L. Rasmussen, and A. M. Krieg. 1996. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol. 157:1840.
10. Cowdery, J. S., J. H. Chace, A. K. Yi, and A. M. Krieg. 1996. Bacterial DNA induces NK cells to produce IFN-γ in vivo and increases the toxicity of lipopolysaccharides. J. Immunol. 156:4570.
11. Sun, S., X. Zhang, D. F. Tough, and J. Sprent. 1998. Type 1 interferon-mediated stimulation of T cells by CpG DNA. J. Exp. Med. 188:2335.
12. Stacey, K. J., M. J. Sweet, and D. A. Hume. 1996. Macrophages ingest and are activated by bacterial DNA. J. Immunol. 157:2116.
13. Chace, J. H., N. A. Hooker, K. L. Mildenstein, A. M. Krieg., and J. S. Cowdery. 1997. Bacterial DNA-induced NK cell IFN-γ production is dependent on macrophage secretion of IL-12. Clin. Immunol. Immunopathol. 84:185.
14. Sparwasser, T., E. S. Koch, R. M. Vabulas, K. Heeg, G. B. Lipford, J. W. Ellwart, and H. Wagner. 1998. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur. J. Immunol. 28:2045.
15. Jakob, T., P. S. Walker, A. M. Krieg, M. C. Udey, and J. C. Vogel. 1998. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J. Immunol. 161:3042.
16. Yi, A. K., D. M. Klinman, T. L. Martin, S. Matson, and A. M. Krieg. 1996. Rapid immune activation by CpG motifs in bacterial DNA: systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. J. Immunol. 157:5394.
17. Yi, A. K., and A. M. Krieg. 1998. Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. J. Immunol. 161:4493.
18. Yi, A. K. R., Tuetken, T. Redford, M. Waldschmidt, J. Kirsch, and A. M. Krieg. 1998. CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J. Immunol. 160:4755.
19. Weiner, G. J., H. M. Liu, J. E. Wooldridge, C. E. Dahle, and A. M. Krieg. 1997. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. USA 94:10833.
20. Moldoveanu, Z., L. Love-Homan, W. Q. Huang, and A. M. Krieg. 1998. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16:1216.
21. Davis, H. L., R. Weeratna, T. J. Waldschmidt, L. Tygrett, J. Schorr, A. M. Krieg., and Weeranta R. 1998. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160:870.
22. Brazolot Millan, C. L., R. Weeratna, A. M. Krieg, C. A. Siegrist, and H. L. Davis. 1998. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc. Natl. Acad. Sci. USA 95:15553.
23. Lipford, G. B., M. Bauer, C. Blank, R. Reiter, H. Wagner, and K. Heeg. 1997. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol. 27:2340.
24. Roman, M., E. Martin-Orozco, J. S. Goodman, M. D. Nguyen, Y. Sato, A. Ronaghy, R. S. Kornbluth, D. D. Richman, D. A. Carson, and E. Raz. 1997. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med. 3:849.
25. Chu, R. S., O. S. Targoni, A. M. Krieg, P. V. Lehmann, and C. V Harding. 1997. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186:1623.
26. Wooldridge, J. E., Z. Ballas, A. M. Krieg, and G. J. Weiner. 1997. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 89:2994.
27. Krieg, A. M., L. Love-Homan, A. K. Yi, and J. T. Harty. 1998. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J. Immunol. 161:2428.
28. Kline, J. N., T. J. Waldschmidt, T. R. Businga, J. E. Lemish, J. V. Weinstock, P. S. Thorne, and A. M. Krieg. 1998. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J. Immunol. 160:2555.
29. Hartmann, G., B. Noll, W. Shen, C. Schetter, and A. M. Krieg. 2000. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol. In press.
30. Hartmann, G., G. Weiner, and A. M. Krieg. 1999. CpG DNA as a signal for growth, activation and maturation of human dendritic cells. Proc. Natl. Acad. Sci. USA 96:9305.
31. + lymphokine-activated killer subset. J. Immunol. 150:17.
32. Hartmann, G., A. Krug, A. Eigler, J. Moeller, J. Murphy, R. Albrecht, and S. Endres. 1996. Specific suppression of human tumor necrosis factor-α synthesis by antisense oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev. 6:291.
33. Hartmann, G., A. Krug, M. Bidlingmaier, U. Hacker, A. Eigler, R. Albrecht, C. J. Strasburger, and S. Endres. 1998. Spontaneous and cationic lipid-mediated uptake of antisense oligonucleotides in human monocytes and lymphocytes. J. Pharmacol. Exp. Ther. 285:920.
34. Hartmann, G., and A. M. Krieg. 1999. CpG DNA and LPS induce distinct patterns of activation in human monocytes. Gene Ther. 6:893.
35. Branda, R. F., A. L. Moore, R. Hong, J. J. McCormack, G. Zon, and R. C. Cunningham. 1996. B-cell proliferation and differentiation in common variable immunodeficiency patients produced by an antisense oligomer to the rev gene of HIV-1. Clin. Immunol. Immunopathol. 79:115.
36. Liang, H., Y. Nishioka, C. F. Reich, D. S. Pisetsky, and P. E. Lipsky. 1996. Activation of human B cells by phosphorothioate oligodeoxynucleotides. J. Clin. Invest. 98:1119.
37. Kimura, Y., K. Sonehara, E. Kuramoto, T. Makino, S. Yamamoto, T. Yamamoto, T. Kataoka, and T. Tokunaga. 1994. Binding of oligoguanylate to scavenger receptors is required lor oligonucleotides to augment NK cell activity and induce IFN. J. Biochem. 116:991.
38. Lee, P. P., M. Ramanathan, C. A. Hunt, and M. R. Garovoy. 1996. An oligonucleotide blocks interferon-γ signal transduction. Transplantation 62:1297.
39. Ramanathan, M., M. Lantz, R. D. MacGregor, M. R. Garovoy, and C. A. Hunt. 1994. Characterization of the oligodeoxynucleotide-mediated inhibition of interferon-γ-induced major histocompalibility complex class I and intercellular adhesion molecule-1. J. Biol. Chem. 269:24564.
40. + cytotoxic T lymphocyte responses in vivo. J. Immunol. 152:1110.
41. Kovarik, J., P. Bozzotti, L. Love-Homan, M. Pihlgren, H. L. Davis, P. H. Lambert, A. M. Krieg, and C. A. Siegrist. 1999. CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J. Immunol. 162:1611.
42. Agrawal, S. 1996. Anlisense oligonucleotides: towards clinical trials. Trends Biotechnol. 14:376.
43. Levin, A. A., D. K. Monteith, J. M. Leeds, P. L. Nicklin, R. S. Geary, M. Butler, M. V. Templin, and S. P. Henry. 1998. Toxicity of oligodeoxynucleotide therapeutic agents. In Handbook of Experimental Pharmacology, Vol. 131: Antisense Research and Application. S. T. Crooke, ed. Springer-Verlag, New York, p. 169.
44. Halpern, M. D., and D. S. Pisetsky. 1995. In vitro inhibition of murine IFN γ production by phosphorothioate deoxyguanosine oligomers. Immunopharmacology 29:47.